GleamWall
中文EN

SBFM Sunshine Biopharma Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1402328 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-5.2%
TTM net income YoY-3.0%
TTM EPS YoY—
Revenue 3-yr CAGR20.2%
Net income 3-yr CAGR—

Margins

Gross margin30.4%
Operating margin-17.2%
Net margin-17.5%
FCF margin—
EBITDA margin-16.3%

Returns

ROE-23.4%
ROA-18.9%
ROIC (approx.)-33.3%
Asset turnover1.08x

Leverage & solvency

Liabilities / assets15.4%
Debt / equity0.00x
Current ratio6.47x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-0.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$9.44M$9.26M$8.09M$8.58M$9.42M$9.41M$8.90M$9.59M
Cost of revenue$6.34M$6.84M$5.91M$5.55M$6.34M$5.99M$6.17M$6.50M
Gross profit$3.10M$2.43M$2.18M$3.03M$3.07M$3.42M$2.73M$3.09M
R&D expense$1,563$13,222$31,724$73,501$119,298$196,232$215,277$149,272
SG&A expense$4.39M$4.04M$3.58M$4.82M$4.16M$5.48M$4.03M$5.13M
Operating income-$1.29M-$1.61M-$1.40M-$1.79M-$1.09M-$2.05M-$1.30M-$2.04M
Interest expense———$0$0$0$0$8,529
Pretax income-$1.29M-$1.56M-$1.24M-$1.73M-$1.02M-$1.98M-$1.22M-$2.29M
Income tax-$63,538$0$0$408,374-$137,438-$209,166-$40,161-$128,737
Net income-$1.22M-$1.56M-$1.24M-$2.14M-$883,820-$1.77M-$1.18M-$2.16M
EBITDA-$1.22M-$1.53M-$1.32M-$1.69M-$990,792-$1.98M-$1.23M-$1.97M
EPS (basic)-5.20-1.15-0.25—-38.80-3.94-0.44—
EPS (diluted)—————-0.82-0.44—
Weighted avg. shares (diluted)—————3.60M2.70M—
Balance sheet
Cash & equivalents$14.62M$13.75M$6.91M$9.12M$9.31M$10.31M$8.12M$9.69M
Receivables$3.89M$4.04M$4.01M$3.46M$4.16M$3.59M$3.45M$3.87M
Inventory$11.66M$12.12M$13.17M$13.47M$14.06M$13.02M$11.86M$11.28M
Current assets$31.00M$30.67M$24.78M$26.85M$27.97M$27.85M$24.48M$25.97M
PP&E, net$361,916$477,047$516,349$557,370$598,087$638,354$519,787$546,055
Goodwill———————$0
Intangibles$1.89M$1.84M$1.92M$1.89M$2.01M$2.49M$3.19M$3.02M
Total assets$33.86M$33.63M$27.93M$30.08M$31.49M$31.97M$29.19M$30.56M
Current liabilities$4.79M$5.62M$5.88M$6.44M$6.65M$5.57M$5.76M$6.31M
Total liabilities$5.22M$6.09M$6.41M$7.04M$7.29M$6.28M$6.48M$7.06M
Shareholders' equity$28.64M$27.54M$21.52M$23.04M$24.20M$25.68M$22.70M$23.50M
Shares outstanding278,3172.39M4.91M24,5304.56M4.56M2.71M2.58M
Cash flow statement
Operating cash flow-$1.38M-$917,977-$2.07M-$1.62M-$747,009-$1.27M-$1.70M-$3.41M
Capital expenditure—$7,015$5,129-$1,039$8,040$160,000$7,490$102,600
Free cash flow—-$924,992-$2.08M-$1.61M-$755,049-$1.43M-$1.70M-$3.51M
Investing cash flow$25,362-$5,120-$104,518-$50,209-$118,295-$550,187-$212,017-$97,770
Financing cash flow$2.23M$7.80M$0$724,500$75,536$3.67M$355,297$1.62M
Depreciation & amortization$74,609$77,974$76,859$98,923$95,821$72,533$64,793$65,399
Share buybacks———$0$0$0$0$0

Free plan shows the latest 8 periods; Pro shows all 68 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.